Combined immune therapy grade IV dermatitis in metastatic melanoma-Reference-Cited by-同舟云学术

Combined immune therapy grade IV dermatitis in metastatic melanoma

Published:2019-02-27 Issue:4 Volume:15 Page:262-265
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Randhawa Manreet¹,Archer Christine¹^ORCID,Gaughran Gregory¹,Miller Andrew²³,Morey Adrienne⁴³,Dua Divyanshu¹³,Yip Desmond¹³

Affiliation:

1. Department of Medical Oncology; The Canberra Hospital; Garran Australian Capital Territory Australia

2. Dermatology Clinic; The Canberra Hospital; Garran Australian Capital Territory Australia

3. ANU Medical School; Australian National University; Acton Australian Capital Territory Australia

4. Department of Anatomical Pathology; The Canberra Hospital; Garran Australian Capital Territory Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.13136/fullpdf

Reference12 articles.

1. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2017

2. Management of toxicities from immunotherapy: eSMO clinical practice guidelines for diagnosis, treatment and follow-up;Haanen;Ann Oncol,2017

3. National Cancer Institute Common Terminology Criteria for Adverse Events 2017 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf

4. Piperacillin and tazobactam: Drug information. UpToDate [Internet]. Lexicomp. UpToDate Inc. 2018 http://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information?search=piperacillin%20tazobactam&source=panel_search_result&selectedTitle=1~93&usage_type=panel&kp_tab=drug_general&display_rank=1

5. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy;Kumar;Front Pharmacol,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events;Pharmaceuticals;2023-11-15

2. Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications;Journal of the European Academy of Dermatology and Venereology;2023-02-04

3. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota;Proceedings of the National Academy of Sciences;2022-06-21

4. Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review;Immunotherapy;2022-04

5. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update;Journal of Clinical Oncology;2021-12-20